OTC · Biotechnology

Adocia S.A. (ADOCY) Stock

$11.80 +0.00% OTC: ADOCY Healthcare

Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides.

Valuation

MetricValue
Price$11.80
Market Cap$170.44M
P/E Ratio-3.91
P/B Ratio49.87
P/S Ratio51.44
EPS (TTM)$-0.81
52-Week High$11.80
52-Week Low$11.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1600.00%
ROA-58.31%
ROCE-215.09%
Gross Margin-1800.00%
Operating Margin-1700.00%
Net Margin-1600.00%
Debt/Equity5.97
Current Ratio1.19

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$11.0M$2.0M$9.0M$1.0M
Operating Profit$-19.0M$-18.0M$-13.0M$-7.0M$-17.0M
Net Profit$-23.0M$-7.0M$-19.0M$-9.0M$-16.0M
EPS$-3.22$-0.86$-1.74$-0.66$-0.81
Op Margin-1341.1%-160.5%-662.5%-79.4%-1229.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$30.0M$31.0M$25.0M$27.0M$28.0M
Total Liabilities$44.0M$44.0M$32.0M$30.0M$27.0M
Cash$15.0M$17.0M$13.0M$8.0M$17.0M
Borrowings$34.0M$33.0M$13.0M$12.0M$9.0M

Latest News

Dow Jones Futures: Google, Tesla Fall On Earnings, Capital Spending Investor's Business Daily · Jul 23, 2026 Australia jobs blow past expectations in June, cements bets of another rate rise Reuters · Jul 23, 2026 Bitwise CIO Names 2 Crypto Bets Best Positioned for the Next Bull Market BeInCrypto · Jul 23, 2026 MegazoneCloud and Korean Re Sign Strategic Agreement to Advance AX PR Newswire · Jul 23, 2026 Messi-less Miami beat Fire 3-2 to spoil Lewandowski's MLS debut AFP · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-15.0M$-5.0M$-16.0M$-6.0M
Investing Cash Flow$-1.0M$22.0M$0$0$-1.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-13.0M$2.0M$-4.0M$-5.0M$11.0M
Free Cash Flow$-20.0M$-15.0M$-5.0M$-16.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.07
EV / EBITDA-4.39
FCF Yield-8.96%
Quick Ratio1.17
Interest Coverage-25.12
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Adocia S.A.

Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorders. Central to its work is the exclusive BioChaperone technological platform, engineered to significantly enhance the performance characteristics of therapeutic proteins. Its robust clinical pipeline features several advanced candidates: Insulin-based treatments: Including BioChaperone Lispro U100 and U200, which are ultra-fast-acting versions derived from rapid insulin lispro; BioChaperone Combo, combining long-acting insulin glargine with rapid-acting insulin lispro; and BioChaperone LisPram, which pairs prandial insulin with pramlintide. Hypoglycemia treatment: BioChaperone Glucagon, an aqueous human glucagon solution specifically designed to manage severe low blood sugar episodes. Other: M1Pram, a derivative combining insulin glargine and pramlintide. The preclinical development programs further expand into bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a co-formulation of insulin glargine and a GLP-1 receptor analogue. Additionally, its preclinical portfolio targets obesity with multi-hormonal products like BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a tripartite blend of pramlintide, glucagon, and exenatide. Adocia has forged a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. for the development and market introduction of BioChaperone Lispro and BioChaperone Combo across China, other parts of Asia, and the Middle East. Established in 2005, the company maintains its headquarters in Lyon, France.

Adocia S.A. is headquartered in FR.

Adocia S.A. (ADOCY) stock trades at $11.80 with a market capitalization of $170.44M. The stock is valued at a price-to-earnings (P/E) ratio of -3.91, price-to-book of 49.87, price-to-sales of 51.44. Over the past 52 weeks the stock has ranged between $11.80 and $11.80, and currently trades at its 52-week high.

On profitability, Adocia S.A. generates a return on equity (ROE) of -1600.00%, return on capital employed of -215.09%, an operating margin of -1700.00%, a net profit margin of -1600.00%.

Official website: www.adocia.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides